Antibodies against erythropoietin and other protein-based therapeutics: An overview

Annals of the New York Academy of Sciences

Volumn 1050, Issue , 2005, Pages 257-265

  Kromminga, Arno ^a,c   Schellekens, Huub ^b  

^a IPM   (Germany)

^b UTRECHT UNIVERSITY   (Netherlands)

^c IPM   (Germany)

Author keywords

Antibodies; Assay; Erythropoietin (EPO); Immunogenicity; Protein; Therapeutics

Indexed keywords

ABCIXIMAB; ALPHA2 INTERFERON; ALPHA2B INTERFERON; ANTIBODY; BETA INTERFERON; BETA1A INTERFERON; BLOOD CLOTTING FACTOR 8 CONCENTRATE; ERYTHROPOIETIN; INTERFERON BETA SERINE; MONOCLONAL ANTIBODY; OKT 3; PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; ANTIBODY DETECTION; BIOASSAY; CONFERENCE PAPER; DRUG MONITORING; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; MARKET; NONHUMAN; RECOMBINANT DNA TECHNOLOGY; RELIABILITY; RISK ASSESSMENT; SIDE EFFECT; VALIDATION PROCESS;

EID: 23744481594     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1313.027     Document Type: Conference Paper

References (27)

1. PORTER, S. 2001. Human immune response to recombinant human proteins. J. Pharm. Sci. 90: 1-11.
2. SCHELLEKENS, H. 2002. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug. Discov. 1: 457-462.
3. RYFF, J.C. & H. SCHELLEKENS. 2002. Immunogenicity of rDNA-derived pharmaceuticals. Trends Pharmacol. Sci. 23: 254-258.
4. SCHELLEKENS, H. 2003. Immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 18: 1257-1259.
5. GOODNOW, C.C. 2001. Pathways for self-tolerance and the treatment of autoimmune diseases. Lancet 357: 2115-2121.
6. CHAKERIAN, B., P. LENZ, D.R. LOWY & J.T. SCHILLER. 2002. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J. Immunol. 169: 6120-6126.
7. CASADEVALL, N., J. NATAF, B. VIRON, et al. 2002. Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346: 469-475.
8. WEBER, G., J. GROSS, A. KROMMINGA, et al. 2002. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J. Am. Soc. Nephrol. 13: 2381-2383.
9. MIRE-SLUIS, A. 2002. Challenges with current technology for the detection, measurement, and characterization of antibodies against biological therapeutics. Biol. Dev. Biol. (Basel) 109: 59-69.
10. WADHWA, M., C. BIRD, P. DILGER, et al. 2003. Strategies for detection, measurement, and characterization of unwanted antibodies induced by therapeutic biologicals. J. Immunol. Methods 278: 1-17.
11. KAWASAKI, E. & G.S. EISENBARTH. 2000. High-throughput radioassays for autoantibodies to recombinant autoantigens. Front. Biosci. 5: e181-e190.
12. TACEY, R., A. GREWAY, J. SMIELL, et al. 2003. The detection of anti-erythropoietin antibodies in human sera and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay. J. Immunol. Methods 283: 317-329.
13. CASADEVAL, N. 2002. Antibodies against rHuEPO: native and recombinant. Nephrol. Dial. Transplant. 17(suppl. 5): 42-47.
14. WADHWA, M., A. MEAGER, P. DILGER, et al. 2000. Neutralizing antibodies to GM-CSF, II-1α and IFN-γ but not other cytokines in human immunoglobulin preparations. Immunology 99: 113-123.
15. SÖRENSEN, P.S., C. ROSS, K.M. CLEMMESEN, et al. 2003. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362: 1184-1191.
16. KOB, M., J. HARVEY, F. SCHAUTZER, et al. 2003. A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta. Mult. Scler. 9: 32-35.
17. DEISENHAMMER, F., M. REINDL, J. HARVEY, et al. 1999. Bioavailability of interferon 1b in MS patients with and without neutralizing antibodies. Neurology 52: 1239-1243.
18. PALLERONI, A.V., A. AGLIONE, M. LABOW, et al. 1997. Interferon immunogenicity: pre-clinical evaluation of interferon-α2a. J. Interferon Cytokine Res. 17: S23-S27.
19. RYFF, J.C. 1997. Clinical investigation of the immunogenicity of interferon-α2a. J. Interferon Cytokine Res. 17: S29-S33.
20. SCHELLEKENS, H., J.C. RYFF & PH. VAN DER MEIDE. 1997. Assays for antibodies to human interferon-α: the need for standardisation. J. Interferon Cytokine Res. 17: 5-8.
21. ROSS, C., K.M. CLEMMESEN, M. SVENSON, et al. 2000. Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration, Ann. Neurol. 48: 706-712.
22. KARPUSAS, M. et al. 1998. The structure of human interferon-β: implications for activity. Cell. Mol. Life Sci. 54: 1203-1216.
23. JACQUEMIN, M.G. & J.M. SAINT-REMY. 1998. Factor VIII immunogenicity. Haemophilia 4: 552-557.
24. KUUS-REICHEL, K., L.S. GRAUER, L.M. KARAVODIN, et al. 1994. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol. 1: 365-372.
25. CLARK, M. 2002. Antibody humanization: a case of the "emperor's new clothes"? Immunol. Today 21: 397-402.
26. PENDLEY, C., A. SCHANTZ & C. WAGNER. 2003. Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Ther. 5: 172-179.
27. DESILVA, B., W. SMITH, R. WEINER, et al. 2003. Recommendations for the bioanalytical method validation of ligand binding assays to support pharmacokinetic assessments of macromolecules. J. Pharm. Biomed. Anal. 20: 1885-1900.